Alethea Capital Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,630
| Closed | -$1.02M | – | 15 |
|
|
2025
Q4 | $1.02M | Sell |
4,630
-1,327
| -22% | -$214K | 0.5% | 8 |
|
|
2025
Q3 | $570K | Buy |
+5,957
| New | +$380K | 0.37% | 7 |
|
|
2025
Q2 | – | Sell |
-14,311
| Closed | -$308K | – | 32 |
|
|
2025
Q1 | $308K | Hold |
14,311
| – | – | 0.23% | 8 |
|
|
2024
Q4 | $385K | Sell |
14,311
-65,597
| -82% | -$1.07M | 0.33% | 17 |
|
|
2024
Q3 | $859K | Hold |
79,908
| – | – | 0.62% | 6 |
|
|
2024
Q2 | $954K | Sell |
79,908
-17
| -0% | -$233 | 0.72% | 6 |
|
|
2024
Q1 | $1.47M | Sell |
79,925
-1,459
| -2% | -$20.9K | 1.19% | 7 |
|
|
2023
Q4 | $1.29M | Hold |
81,384
| – | – | 1.49% | 6 |
|
|
2023
Q3 | $1.53M | Hold |
81,384
| – | – | 1.88% | 5 |
|
|
2023
Q2 | $1.84M | Sell |
81,384
-2,476
| -3% | -$58.2K | 1.97% | 5 |
|
|
2023
Q1 | $2.13M | Hold |
83,860
| – | – | 2.25% | 5 |
|
|
2022
Q4 | $1.27M | Hold |
83,860
| – | – | 1.22% | 6 |
|
|
2022
Q3 | $1.05M | Hold |
83,860
| – | – | 1.33% | 6 |
|
|
2022
Q2 | $819K | Sell |
83,860
-13,103
| -14% | -$162K | 1.03% | 7 |
|
|
2022
Q1 | $1.61M | Buy |
96,963
+111
| +0.1% | +$1.88K | 1.46% | 6 |
|
|
2021
Q4 | $2.46M | Buy |
96,852
+38,250
| +65% | +$1.19M | 2.09% | 5 |
|
|
2021
Q3 | $2.63M | Hold |
58,602
| – | – | 2.31% | 5 |
|
|
2021
Q2 | $2.37M | Buy |
58,602
+420
| +0.7% | +$17.8K | 1.49% | 5 |
|
|
2021
Q1 | $3.1M | Buy |
58,182
+475
| +0.8% | +$23.5K | 1.89% | 5 |
|
|
2020
Q4 | $2.31M | Sell |
57,707
-7
| -0% | -$348 | 1.16% | 6 |
|
|
2020
Q3 | $3.29M | Buy |
57,714
+6,295
| +12% | +$445K | 2.23% | 6 |
|
|
2020
Q2 | $3.79M | Buy |
51,419
+6,676
| +15% | +$433K | 2.22% | 4 |
|
|
2020
Q1 | $2.22M | Buy |
44,743
+16,527
| +59% | +$990K | 1.44% | 6 |
|
|
2019
Q4 | $2.17M | Hold |
28,216
| – | – | 0.93% | 5 |
|
|
2019
Q3 | $1.13M | Hold |
28,216
| – | – | 0.71% | 7 |
|
|
2019
Q2 | $948K | Hold |
28,216
| – | – | 0.62% | 20 |
|
|
2019
Q1 | $1.5M | Buy |
28,216
+4,098
| +17% | +$225K | 1.06% | 11 |
|
|
2018
Q4 | $1.13M | Buy |
24,118
+2,250
| +10% | +$161K | 1.65% | 16 |
|
|
2018
Q3 | $1.92M | Buy |
21,868
+16,413
| +301% | +$1.45M | 2.88% | 6 |
|
|
2018
Q2 | $567K | Buy |
5,455
+1,560
| +40% | +$147K | 0.97% | 23 |
|
|
2018
Q1 | $312K | Buy |
3,895
+1,282
| +49% | +$175K | 0.42% | 67 |
|
|
2017
Q4 | $355K | Buy |
+2,613
| New | +$396K | 0.56% | 60 |
|
Alethea Capital Management's CDTX Position: Q1 2026 in Review
Alethea Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 4,630 shares — an estimated $1.02M sold.
Alethea Capital Management first reported a position in CDTX in Q4 2017 and held it in 32 quarters. The position peaked at $3.79M in Q2 2020. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Alethea Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Alethea Capital Management sold 4,630 Cidara Therapeutics shares in Q1 2026, an estimated $1.02M.
- Alethea Capital Management first reported a position in Cidara Therapeutics in Q4 2017 and held it in 32 quarters.
- Alethea Capital Management's Cidara Therapeutics position peaked at $3.79M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.